Once a marketing authorisation (MA) application has been submitted, the dossier goes through a long assessment process until the MA is granted. During this time, company strategies, suppliers and business plans may change. However, the MA process is not as flexible as the post-authorisation phase. Some steps cannot be taken at all, some are possible only under certain conditions, and others can be started without waiting for the MA.
Can the dossier be changed?
Changes to authorised products are made through variation applications. For products still in the MA process, however, TİTCK has not accepted company-initiated variations since 20 December 2021. The only route is a “zorunlu hal başvurusu” (mandatory-circumstance application).
The Regulation defines this as an application containing a change that becomes mandatory during the authorisation process and that the Agency accepts as mandatory at the applicant’s request. It is submitted under the document type “Zorunlu Haller Kapsamındaki CTD Değişim Başvurusu” (CTD change application under mandatory circumstances), and the justification is assessed first. If the justification is accepted, the documents are submitted to the Licensing Unit with reference to the variation guideline.
Examples assessed through this route in TİTCK’s frequently asked questions include:
- Addition of an indication during the assessment
- A change of the laboratory performing batch analyses
- A name change of the active substance or finished product manufacturing site
Whether a justification is accepted as “mandatory” is at the Agency’s discretion. Deferring a planned change until after authorisation is often the more predictable option.
Can an MA application be transferred?
Yes. Under Article 27 of the Regulation, the natural person or commercial company that applied for an MA may transfer the rights arising from the application to another natural person or commercial company. The conditions in Article 26 on the transfer of MAs must be met. In other words, a transfer does not require waiting for the MA, but the transfer documents must be as complete as for an MA transfer.
Can a price be obtained before the MA?
No. The Pricing Communiqué defines the “applicant” as the company holding the MA or permit. The price application therefore becomes possible only once the MA is granted. The sequence is also set out in the Regulation: for products placed on the market for the first time, the sales permit is granted for a product whose price has been approved by the Agency.
The phrase “ruhsata esas fiyat” (price based on the MA), often heard in the sector, is not a term defined in the legislation. TİTCK uses “ruhsata esas” to refer to information registered in the MA. The application meant is called “İlk Kez Fiyat Değerlendirme ve Fiyat Listesinde Yayımlama Başvurusu” (application for first-time price assessment and publication in the price list). It is submitted through İFPAS using the product’s barcode, and the barcode can be selected only after the Department of Drug Licensing has defined it in the system.
For products that cannot be priced under the Communiqué’s rules, there is also the Price Evaluation Commission (FDK) route. FDK applications can be made for products both on and off the price list, but only during the application windows announced by the Agency. The Commission meets once a year in ordinary session and may also meet extraordinarily when needed. New molecules authorised in Türkiye for the first time are likewise priced by the FDK on the company’s declaration. For a product not on the list, the price approved by the FDK is notified by official letter, after which the first-time price application must be submitted. This route, too, opens only after the MA.
For generics, the MA date directly affects the price. The Communiqué provides that, for generics above a certain price threshold, the source price is set using year-based rates: 80% in the first year, 75% in the second and 70% in the third. The rates run from the date the first generic is placed on the market. However, if the first generic is not launched within six months of its MA, the period starts automatically six months after the MA date. If launch is blocked by data exclusivity or a patent, the period starts when that protection ends.
When can a reimbursement application be made?
For an application to SGK for inclusion in the reimbursement list, the MA certificate and the TİTCK price list are mandatory documents. A reimbursement application can therefore be made only after the MA and the price have been obtained. The sales permit, by contrast, is not as strict a prerequisite: it is enough to upload the sales permit by the 15th of the month following the final application date for the relevant Reimbursement Commission working period.
There is one more exception: applications under the alternative reimbursement model do not require the TİTCK price list.
Once the product is on the list, the clock starts. The distribution document showing that the product is on the market must be submitted to SGK within five months. Otherwise the product is set to passive in the provision system, and if the document has still not been submitted by the end of the tenth month, the product is removed from the list.
What can be done while the process continues?
- Scientific advice: TİTCK can provide scientific advice, for a fee, before an MA application or during the authorisation process.
- Timely responses to deficiency letters: The Agency’s requests for information and documents must be answered within 30 days, either with the documents or with a dated statement. All requested documents are submitted in a single application. (Details: Procedural rejection and the 30-day response period)
- Post-authorisation preparation: The documents needed for the price declaration, sales permit and reimbursement dossier can be prepared during the process, so that the applications can be made without delay once the MA is granted.
Sources: Regulation on the Marketing Authorisation of Human Medicinal Products (Official Gazette 11.12.2021/31686, current text), Articles 4, 6, 13, 26, 27 and 28; TİTCK Department of Drug Licensing Frequently Asked Questions (16.02.2024); Communiqué on the Pricing of Human Medicinal Products (Official Gazette 29.08.2026/33355), Articles 3, 8 and 14; TİTCK Pricing Guideline (EDİT-KLVZ-11), Rev. 3, 18.11.2026, section 8.1.3; TİTCK İFPAS Applicant User Guide (Version 4); SGK Drug Reimbursement Regulation (current text), Article 14; SGK Procedures and Principles on Drug Applications (15.09.2026), Articles 5 and 6. This article is for general information; current legislation and Agency announcements prevail.
